<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941107-2-00101</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <TABLE>  <!-- PJG tableformat 3,L2,tp0,i1,s25,11,r25  -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank;  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Chemical  <!-- PJG 007 0150 intable --> 1CAS registry No.  <!-- PJG 007 0150 intable --> 1Committee recommendations  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 1. Dimethyl adipate  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 627&hyph;93&hyph;0  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -Carcinogenicity  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Genotoxicity  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Sensory irritation  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Dermal subchronic  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Reproductive and developmental effects (other than rat)  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Neutrotox- <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &blank;icity  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Metabolism and toxicity (using human upper respiratory tissues)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. 2,3-Butanedione  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 431&hyph;03&hyph;8  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -Carcinogenicity  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Metabolism  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> - <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=3 --> In vivo  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> genotoxicity  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. 2,2 <!-- PJG 0020 minuteslatlong --> &rsquo;-Dipyridyl  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 366&hyph;18&hyph;7  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -No testing  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Methyl styryl  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 122&hyph;57&hyph;6  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -Metabolism  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Pharma- <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &blank;cokinetics  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> - <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=3 --> In vivo  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> genotoxicity  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> -Mechanistic studies  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. N-Bromosuc- cinimide  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 128&hyph;08&hyph;5  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -No testing  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 6. 5-Nitroindazole  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 5401&hyph;94&hyph;5  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> -No testing  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The ICCEC also recommended that two chemicals, ecdysterone and 2,3-dichloropropylene, be removed from consideration for testing at this time based on lack of evidence of human exposure with the understanding that these chemicals may be reconsidered at a later date if actual human exposure is demonstrated.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Interested parties are requested to submit pertinent information on all of the nominated chemicals. The following types of data are of particular relevance:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (1) Modes of production, present production levels, and occupational exposure potential;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) Uses and resulting exposure levels, where known;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (3) Completed, ongoing and/or planned toxicological testing in the public or private sector including detailed experimental protocols and results; and  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (4) Results of toxicological studies of structurally related compounds.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Please submit all information in writing (by 30 days after date of publication) to Dr. Zeigler by mail or by FAX, (919) 541&hyph;4704. Any submissions received after the above date will be accepted and utilized if possible.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: October 31, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Richard A. Griesemer,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, NIEHS.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;27468 Filed 11&hyph;4&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;M  <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            